Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in ...

Within the iShares Nasdaq Biotechnology ETF (IBB), the biotechnology and pharmaceutical subgroups have a combined weight of ~97.5% of IBB’s portfolio. The moving average provides investors with a ...

Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. The biotech focused on low-dose results from its latest phase 2 trial, rather than the overall ...

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:LXRX), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Lexicon Pharmaceuticals has laid off 100 people in its offices in The Woodlands and Princeton, N.J., as part of an ongoing reorganization. Company spokesman Steven Tragash said Lexicon is reducing its ...